Nexalin's Neurostimulation Device Shows Significant Cognitive Improvements in Alzheimer's Disease Trial
Key Insights
Nexalin's Gen-2 SYNC (search) neurostimulation device demonstrated statistically significant improvements in cognitive performance in patients with mild Alzheimer's disease (search), with MMSE and MoCA scores showing meaningful gains compared to sham treatment.
The randomized, sham-controlled trial published in Radiology revealed that 40-Hz DIFS (search) technology enhanced brain network connectivity between the hippocampus (search) and critical cortical regions involved in memory and executive function.
The study represents the first fMRI-confirmed evidence that a 40-Hz, 15 mA electrical waveform can increase hippocampal-cortical connectivity in Alzheimer's patients, with no adverse events reported during treatment.
Nexalin Technology (search) has announced positive results from a randomized, sham-controlled clinical trial demonstrating that its Gen-2 SYNC (search) neurostimulation device significantly improves cognitive performance and brain connectivity in patients with mild Alzheimer's disease (search). The study, published in Radiology, the flagship journal of the Radiological Society of North America, provides what the company describes as "the strongest peer-reviewed evidence to date of a non-invasive, drug-free intervention delivering measurable neurological and clinical benefits in AD."
Significant Cognitive Improvements Demonstrated
The trial showed that patients receiving Nexalin's Gen-2 SYNC (search) 40-Hz Deep Intracranial Frequency Stimulation (DIFS (search)) device achieved statistically significant improvements in standardized cognitive assessments. Participants demonstrated meaningful gains in Mini-Mental State Examination (MMSE) scores and Montreal Cognitive Assessment (MoCA) scores compared to baseline, with these improvements reaching statistical significance when compared to the sham group (P = .001 and .03, respectively).
The study also revealed a significant correlation between increased connectivity and functional outcomes, with enhanced connectivity between the hippocampus (search) and middle cingulate gyrus (search) correlating with improvement on the Boston Naming Test (r = 0.65, FDR-adjusted P = .008).
Neuroimaging Confirms Mechanism of Action
Resting-state functional MRI analysis provided crucial mechanistic insights, revealing enhanced functional connectivity between the hippocampus (search) and key cortical regions critical to memory and executive function, including the middle cingulate gyrus (search) and middle frontal gyrus (search). The neuroimaging data showed statistically significant increases in functional connectivity across broader cognitive networks, including the default mode network, frontoparietal networks, and visual and auditory systems—all commonly disrupted in Alzheimer's disease (search).
This study marks the first demonstration with fMRI confirmation that a 40-Hz, 15 mA electrical waveform can increase hippocampal-cortical connectivity in Alzheimer's patients while being associated with measurable cognitive improvement.
Safety Profile and Technology Platform
The trial reported no adverse events during the treatment period, reinforcing the safety and tolerability profile of Nexalin's DIFS (search) technology. The Gen-2 SYNC (search) device utilizes Nexalin's proprietary 15 milliamp implementation of transcranial alternating current stimulation (tACS), designed to penetrate deep brain structures associated with neurological disorders.
"The results of this study represent a significant milestone for Nexalin's technology platform," said Mark White, CEO of Nexalin. "The data clearly supports our belief that Nexalin's non-invasive deep, frequency-specific neurostimulation can meaningfully improve cognitive performance in patients with Alzheimer's disease (search)."
Market Position and Regulatory Status
White noted that with a global Alzheimer's disease (search) market projected to exceed $20 billion annually, these findings strengthen the company's strategy to deliver alternatives to pharmacologic treatments for neurodegenerative conditions. The Gen-2 SYNC (search) 15 mA DIFS (search) device has already received approval in China for treating depression (search) and insomnia (search), and is approved in Brazil and Oman for anxiety (search), depression, and insomnia treatment.
The new Alzheimer's data supports Nexalin's broader global regulatory strategy to expand treatment indications with various international regulatory agencies, including the FDA in the United States. The company positions itself as a leader in Deep Intracranial Frequency Stimulation technology, focusing on non-invasive bioelectronic medical solutions for mental health and neurological conditions.